New cancer clinical trial: A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Published on: August 16, 2018 at 12:00PM
Conditions:   Breast Cancer;   HER2+ Breast Cancer
Interventions:   Biological: VRP-HER2;   Biological: Pembrolizumab
Sponsors:   Herbert Lyerly;   Merck Sharp & Dohme Corp.
Not yet recruiting
https://ift.tt/2vNgJ0q